Evidence map›Paper›PMID 32447175›Full record

ArticleProstaglandins, leukotrienes, and essential fatty acids2020

SC411 treatment can enhance survival in a mouse model of sickle cell disease.

Celeste Y C Wu, Miguel A Lopez-Toledano, Ahmed A Daak, Garrett A Clemons, Cristiane T Citadin, Frederick D Sancilio, Adrian L Rabinowicz, Alireza Minagar, Jake T Neumann, Reggie H C Lee and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostaglandins, leukotrienes, and essential fatty acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. The role of serum/glucocorticoid-regulated kinase 1 in brain function following cerebral ischemia.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Celeste Y C WuDepartment of Neurology, Louisiana State University Health Sciences Center, 1501 Kings Hwy Shreveport, LA, USA.
Miguel A Lopez-ToledanoSancilio & Company, Inc, Stuart, FL, USA; Center of Molecular Biology and Biotechnology (CMBB), Florida Atlantic University, USA.
Ahmed A DaakSancilio & Company, Inc, Stuart, FL, USA; Center of Molecular Biology and Biotechnology (CMBB), Florida Atlantic University, USA.
Garrett A ClemonsDepartment of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Cristiane T CitadinDepartment of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Frederick D SancilioSancilio & Company, Inc, Stuart, FL, USA; Center of Molecular Biology and Biotechnology (CMBB), Florida Atlantic University, USA.
Adrian L RabinowiczSancilio & Company, Inc, Stuart, FL, USA; Center of Molecular Biology and Biotechnology (CMBB), Florida Atlantic University, USA.
Alireza MinagarDepartment of Neurology, Louisiana State University Health Sciences Center, 1501 Kings Hwy Shreveport, LA, USA.
Jake T NeumannDeaprtment of Biomedical Sciences, West Virginia School of Osteopathic Medicine, Lewisburg, WV, USA.
Reggie H C LeeDepartment of Neurology, Louisiana State University Health Sciences Center, 1501 Kings Hwy Shreveport, LA, USA.
Hung Wen LinDepartment of Neurology, Louisiana State University Health Sciences Center, 1501 Kings Hwy Shreveport, LA, USA; Department of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center, Shreveport, LA, USA. Electronic address: hlin2@lsuhsc.edu.
Louisiana State University Health Sciences Center Shreveport · USFlorida Atlantic University · USWest Virginia School of Osteopathic Medicine · US

Funding

American Heart Association-American Stroke Association 17GRNT33660336
6 · The paper itself

Abstract

Sickle cell disease (SCD) is one of the most common inherited blood disorder among African Americans affecting 70,000-100,000 individuals in the United States. It is characterized by abnormal hemoglobin (HbS) which develops into severe hemolytic anemia and vaso-occlusive crisis. Therefore, patients with SCD suffer from a chronic state of inflammation, which is responsible for multiple organ damage, ischemic attacks, and premature death. Another major hallmark of SCD patients is the abnormally low levels of omega-3 fatty acids, especially docosahexaenoic acid (DHA) in their red blood cell membranes. Treatment with DHA can reduce red blood cell adhesion and enhance cerebral blood flow, thus, our main goal is to investigate the effect of SC411, which is a novel, highly purified DHA ethyl ester formulation with a proprietary delivery platform in SCD. Utilizing a transgenic mouse model of SCD (HbSS-Townes) and recurrent hypoxic challenges (10%O

Indexed as

Anemia, Sickle CellAnimalsArachidonic AcidCerebrovascular CirculationDisease Models, AnimalDocosahexaenoic AcidsEstersHumansMaleMemory, Short-TermMiceMice, TransgenicSurvival AnalysisTreatment OutcomeArachidonic AcidDocosahexaenoic AcidsEstersAgingCerebral blood flowDocosahexaenoic acidNeuroinflammationSickle cell diseaseWorking memory

Identifiers

PMID32447175
PMCPMC13037716
OpenAlexW3021578348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.